Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.

The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report

Open access

Abstract

BACKGROUND: In vitro diagnostic (IVD) investigations are indispensable for routine patient management. Appropriate testing allows early-stage interventions, reducing late-stage healthcare expenditure (HCE). AIM: To investigate HCE on IVDs in two developed markets and to assess the perceived value of IVDs on clinical decision-making. Physician-perceived HCE on IVD was evaluated, as well as desired features of new diagnostic markers. METHODS: Past and current HCE on IVD was calculated for the US and Germany. A total of 79 US/German oncologists and cardiologists were interviewed to assess the number of cases where: physicians ask for IVDs; IVDs are used for initial diagnosis, treatment monitoring, or post-treatment; and decision-making is based on an IVD test result. A sample of 201 US and German oncologists and cardiologists was questioned regarding the proportion of HCE they believed to be attributable to IVD testing. After disclosing the actual IVD HCE, the physician's perception of the appropriateness of the amount was captured. Finally, the association between physician-rated impact of IVD on decision-making and perceived contribution of IVD expenditure on overall HCE was assessed. RESULTS: IVD costs account for 2.3% and 1.4% of total HCE in the US and Germany. Most physicians (81%) believed that the actual HCE on IVDs was >5%; 19% rated the spending correctly (0-4%, p<0.001). When informed of the actual amount, 64% of physicians rated this as appropriate (p<0.0001); 66% of decision-making was based on IVD. Significantly, more physicians asked for either additional clinical or combined clinical/health economic data than for the product (test/platform) alone (p<0.0001). CONCLUSIONS: Our results indicate a poor awareness of actual HCE on IVD, but a high attributable value of diagnostic procedures for patient management. New markers should deliver actionable and medically relevant information, to guide decision-making and foster improved patient outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0149856

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Percentage of public and private HCE of GDP (pie) in the US and Germany in 2013. Thin lines, public HCE; bold lines, private HCE without out-of-pocket; black fill, out-of-pocket HCE; white fill, rest of GDP (non-HCE) HCE, healthcare expenditure; GDP, gross domestic product; $B, US$ billion.
Fig 1 Percentage of public and private HCE of GDP (pie) in the US and Germany in 2013. Thin lines, public HCE; bold lines, private HCE without out-of-pocket; black fill, out-of-pocket HCE; white fill, rest of GDP (non-HCE) HCE, healthcare expenditure; GDP, gross domestic product; $B, US$ billion.CC BY · PubMed Central
Fig 2 (A) Percentage of HCE on IVD in 2013 and (B) evolution of HCE on IVD 1993–2013. HCE, healthcare expenditure; IVD, in vitro diagnostics; $ B, US$ billion.
Fig 2 (A) Percentage of HCE on IVD in 2013 and (B) evolution of HCE on IVD 1993–2013. HCE, healthcare expenditure; IVD, in vitro diagnostics; $ B, US$ billion.CC BY · PubMed Central
Fig 3 Causal loop diagram displaying the root causes for over- and under-utilization of IVD testing. Key drivers displayed in boxes; antecedents and secondary drivers displayed as plain text. IVD, in vitro diagnostic; →(+), positive causal links amplifying the behavior of target variable.
Fig 3 Causal loop diagram displaying the root causes for over- and under-utilization of IVD testing. Key drivers displayed in boxes; antecedents and secondary drivers displayed as plain text. IVD, in vitro diagnostic; →(+), positive causal links amplifying the behavior of target variable.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 1

  1. Quest Diagnostics 31st Annual J. P. Morgan Healthcare Conference January 9, 2013. Available: http://ir.questdiagnostics.com/phoenix.zhtml?c=82068&p=irol-presentations.

Cited by

See all 233

Metadata

Authors
Rohr, U.-P., Binder, C., Dieterle, T., Giusti, F., Messina, C. G. M., Toerien, E., Moch, H., & Schäfer, H. H.
Affiliations
  • University Hospital Zurich (CH)
  • Kantonsspital Baselland (CH)
  • European Organisation for Research and Treatment of Cancer (NL)
  • F. Hoffmann-La Roche AG (CH)
Corresponding author
Schäfer, Hans Hendrik
Venue
PLOS ONE
Published
2016-03-04
Volume
11
Issue
3
Pages
e0149856
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2291253625
Cited by
229
References
44
Citations by year
2026: 15 · 2025: 21 · 2024: 43 · 2023: 22 · 2022: 18 · 2021: 23 · 2020: 22 · 2019: 21 · 2018: 20 · 2017: 14 · 2016: 10
FWCI
40.31
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • edoc (University of Basel) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • UpSpace Institutional Repository (University of Pretoria) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
  • Zurich Open Repository and Archive (University of Zurich)
Topics
  • Health Sciences › Health Professions › General Health Professions › Healthcare cost, quality, practices
  • Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
health care expenditure, physician perceptions, clinical decision-making, diagnostic biomarkers, cost awareness, clinical management
MeSH terms
Algorithms, Cardiology, Cost-Benefit Analysis, Data Collection, Diagnostic Tests, Routine, Germany, Humans, Medical Oncology, Practice Patterns, Physicians', Surveys and Questionnaires, United States, Health Care Costs, Decision Support Systems, Clinical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. https://app.cochat.ai/papers/10.1371/journal.pone.0149856
The paper
Rohr, U.-P., Binder, C., Dieterle, T., Giusti, F., Messina, C. G. M., Toerien, E., Moch, H., & Schäfer, H. H. (2016). The Value of In Vitro Diagnostic Testing in Medical Practice: A Status Report. PLOS ONE. https://doi.org/10.1371/journal.pone.0149856

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.